DOCSLIB.ORG

UNFPA Contraceptives Price Indicator Year 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UNFPA Contraceptives Price Indicator Year 2015 UNFPA Contraceptives Price Indicator Year 2015 UNFPA UNFPA UNFPA Sales Number of Couple Years Number of LTA Unit Sales Unit Annual Median Price Price UNFPA Average Unit Cost Protection Clients support Annual Cost Price Price Contraceptive Method Product UOM Quantity Total Cost $ MSH Price Compared to LTA UNFPA $* Conversion in the year per CYP** Compared Compared Procured Indicator*** MSH suppliers Factor (Qty/CYP) to Last to Last Indicator Year Year 97,569,994 $ 116,452,974 42,795,208 $ 2.72 Male Condom Male condom, overall gross 14 4,669,503 $ 18,170,906 $ 3.89 0.83 5,603,404 $ 3.24 $ 4.910 -20.8% -0.49% -3.76% Male condom, standard gross 14 4,141,518 $ 16,082,937 $ 3.88 0.83 4,969,822 $ 3.24 -0.08% -2.72% Male condom, special design gross 14 527,985 $ 2,087,969 $ 3.95 0.83 633,582 $ 3.30 -0.88% -8.85% Female Condom Female condom, Overall Piece 2 14,523,244 $ 7,095,808 $ 0.49 120.00 121,027 $ 58.63 $ 0.742 -34.2% -17.71% -3.43% Female condom, FC2 Piece 1 13,196,000 $ 6,631,273 $ 0.50 120.00 109,967 $ 60.30 -4.91% -0.71% Natural rubber latex female condom Piece 1 1,327,244 $ 464,535 $ 0.35 120.00 11,060 $ 42.00 - - IUD CopperT, Overall Set 4 1,478,727 $ 449,611 $ 0.30 0.22 6,802,144 $ 0.07 $ 1.089 -72.1% 0.00% -5.86% CupperT 380 Set 4 1,478,727 $ 449,611 $ 0.30 0.22 6,802,144 $ 0.07 1.57% -5.73% - - - - - Progestagen Only Pill Progestagen Only Pill, Overall Cycle 2 5,531,320 $ 1,891,565 $ 0.34 15.00 368,755 $ 5.13 $ 0.435 -21.5% -0.46% 9.19% Lynestrenol 0.5 mg Cycle 1 2,258,858 $ 909,827 $ 0.40 15.00 150,591 $ 6.04 $ 0.430 -6.33% -0.80% -2.70% Levonorgestrel 0.03 mg Cycle 1 3,272,462 $ 981,739 $ 0.30 15.00 218,164 $ 4.50 $ 0.441 -31.96% 0.00% 0.00% Combined Low Dose Pill Combined Low Dose Pill, Overall Cycle 5 27,730,932 $ 7,999,445 $ 0.29 15.00 1,848,729 $ 4.33 $ 0.583 -50.5% -2.76% -9.86% Desorgestrel 0.15mg + Ethinyle Estradiol 0.03mg Cycle 3 2,148,463 $ 1,470,871 $ 0.68 15.00 143,231 $ 10.27 $ 0.720 -4.91% -0.16% 1.92% Levonorgestrel 0.15mg + Ethinyle estradiol 0.03mg Cycle 4 25,581,551 $ 6,528,230 $ 0.26 15.00 1,705,437 $ 3.83 $ 0.514 -50.33% 0.00% -5.44% Levonorgestrel 0.15mg + Ethinyle Estradiol 0.03mg X3 Cycle 1 918 $ 344 $ 0.37 15.00 61 $ 5.62 $ 0.514 -27.14% Emergency Pill Emergency Pill, Overall Pack 3 1,380,628 $ 512,108 $ 0.37 20.00 69,031 $ 7.42 $ 0.527 -29.7% 0.00% 25.32% Levonorgestrel 1.5mg Pack 3 520,275 $ 309,082 $ 0.59 20.00 26,014 $ 11.88 $ 0.821 -27.60% 0.00% -9.99% Levonorgestrel 0.75mg x2 Pack 2 860,353 $ 203,026 $ 0.24 20.00 43,018 $ 4.72 $ 0.234 0.80% 0.00% -5.53% Injectable Contraceptive Injectable Contraceptive, Overall Vial/Ampoule 3 36,273,250 $ 29,274,473 $ 0.81 6.50 8,598,604 $ 5.25 $ 1.201 -32.8% -12.26% -2.49% Medroxyprogesterone acetate 150mg Vial 2 28,679,550 $ 21,360,208 $ 0.74 4.00 7,169,888 $ 2.98 $ 0.747 -0.32% -11.20% -3.64% Sterilie Medroxyprogesterone (104mg/0.65ml) 1 2,791,000 $ 2,639,800 $ 0.95 4.00 697,750 $ 3.78 - - Norethisterone enanthate 200mg Ampoule 1 3,968,900 $ 4,565,735 $ 1.15 6.00 661,483 $ 6.90 $ 1.654 -30.46% -11.54% -11.51% Norethisterone enanthate 50 mg + Estradiol valerate 5mg 1 833,800 $ 708,730 $ 0.85 12.00 69,483 $ 10.20 $ 1.974 - - Subdermal Implants Subdermal Implants, Overall Set 2 5,982,390 $ 51,059,058 $ 8.53 0.33 19,383,514 $ 2.83 $ 11.091 -23.0% 0.00% -1.39% Etonogestrel 68mg x 1 Set 1 2,576,591 $ 22,024,766 $ 8.55 0.40 6,441,478 $ 3.42 $ 11.075 -22.82% 0.00% -4.22% Etonogestrel 68mg x 1 (5 sets) Set 1 - Levonorgestrel 75mg x 2 Set 1 3,405,799 $ 29,034,292 $ 8.52 0.26 12,942,036 $ 2.24 $ 11.106 -23.24% 0.00% 0.29% * Calculated based on Total Annual Cost/Annual Quantity Procured; Item cost only, other costs are not included. ** Calculated in accordance to: http://www.usaid.gov/what-we-do/global-health/family-planning/couple-years-protection-cyp *** MSH Price Indicator 2014 (2015 version is not available yet): http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf Number and % of items with better price compared to previous year 21 95% Number and % of items UNFPA has better price compared to MSH 18 95% when cost is more than $10 When UNFPA's current price is more than 10% higher than previous years or other procurers when cost is between $5 to $10 When UNFPA's current price is less than 10% higher than previous years or other procurers when cost is between $1 to $5 When UNFPA's current price is better than previous years or other procurers when cost is under $1.
Load more

Recommended publications
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • A Rare Case of Cerebral Venous Sinus Thrombosis (CVST) Induced by Norethisterone Enanthate: Report from a Medical University Hospital in Bangladesh
    Case Report Annals of Clinical Case Reports Published: 25 Jan, 2019 A Rare Case of Cerebral Venous Sinus Thrombosis (CVST) Induced by Norethisterone Enanthate: Report from a Medical University Hospital in Bangladesh Raknuzzaman1, Anis Ahmed1*, Masud Rana1, Kazi Jannat Ara1 and Dewan Md Emdadul Hoque1 1Department of Neurology, Bangabandhu Sheikh Mujib Medical University, Bangladesh 2Department of Epidemiology and Preventive Medicine, International Centre for Diarrhoeal Disease Research, Bangladesh Abstract Cerebral Venous Sinus Thrombosis (CVST) is a rare condition and the association between norethisterone enanthate and CVST in the literature has very seldom been reported. In this case report, a 22-year-old unmarried woman of Bangladesh presented with acute onset of headache and vomiting with history of oral intake of 5 mg norethisterone thrice daily during past 2 years for menstrual disorder. She had no history of seizure, visual disturbances, and neck stiffness, imbalance of gait and weakness of any limbs, any sensory complaints or any episode of unconsciousness during the course of illness. Bilateral papilloedema was present with more marked on left eye and serum homocysteine level was high. A brain CT scan, MRI and Magnetic Resonance Venogram (MRV) revealed thrombosed anterosuperior segment of superior sagittal sinus. She was diagnosed to have CVST due to norethisterone and was treated with low molecular weight heparin, followed by Rivaroxaban, Vitamin B12, Vitamin B6 and Folic acid. She made a complete recovery after one month of intake of rivaroxaban and withdrawn of norethisterone. Keywords: Cerebral venous sinus thrombosis; Norethisterone enanthate; Hyperhomocysteinemia; OPEN ACCESS Rivaroxaban *Correspondence: Introduction Anis Ahmed, Department of Neurology, Cerebral Venous Sinuses Thrombosis (CVST) is rare type of stroke with the annual incidence Bangabandhu Sheikh Mujib Medical ranging from 0.22 to 1.57 per 100,000 populations, affecting young individuals and mostly women University, Bangladesh, Tel: [1-3].
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    PHARMACEUTICALS volume 100 A A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007).
    [Show full text]
  • Use of Postmenopausal Hormone Therapy and Risk of Alzheimer’S BMJ: First Published As 10.1136/Bmj.L665 on 6 March 2019
    RESEARCH Use of postmenopausal hormone therapy and risk of Alzheimer’s BMJ: first published as 10.1136/bmj.l665 on 6 March 2019. Downloaded from disease in Finland: nationwide case-control study Hanna Savolainen-Peltonen,1,2 Päivi Rahkola-Soisalo,1 Fabian Hoti,3 Pia Vattulainen,3 Mika Gissler,4,5,6 Olavi Ylikorkala,1 Tomi S Mikkola1,2 1University of Helsinki and ABSTRACT ratio 1.09, 95% confidence interval 1.05 to 1.14) and Helsinki University Hospital, OBJECTIVES those of oestrogen-progestogen (1.17, 1.13 to 1.21). Obstetrics and Gynecology, To compare the use of hormone therapy between The risk increases in users of oestrogen-progestogen Haartmaninkatu 2, PO Box 140, FIN-00029 HUS, 00029 Finnish postmenopausal women with and without a therapy were not related to different progestogens Helsinki, Finland diagnosis for Alzheimer’s disease. (noreth isterone acetate, medroxyprogesterone 2 Folkhälsan Research Center, DESIGN acetate, or other progestogens); but in women Biomedicum, Helsinki, Finland younger than 60 at hormone therapy initiation, 3 Nationwide case-control study. EPID Research Oy, Espoo, these risk increases were associated with hormone Finland SETTING therapy exposure over 10 years. Furthermore, the 4National Institute for Health Finnish national population and drug register, age at initiation of systemic hormone therapy was and Welfare, Helsinki, Finland between 1999 and 2013. 5Karolinska Institute, not a decisive determinant for the increase in risk Department of Neurobiology, PARTICIPANTS of Alzheimer’s disease. The exclusive use of vaginal Care Sciences and Society, All postmenopausal women (n=84 739) in Finland estradiol did not affect the risk of the disease (0.99, Division of Family Medicine, who, between 1999 and 2013, received a diagnosis of 0.96 to 1.01).
    [Show full text]
  • Norethisterone Enanthate Has Neither a Direct Effect on the Testis Nor On
    European Journal of Endocrinology (2005) 152 655–661 ISSN 0804-4643 EXPERIMENTAL STUDY Norethisterone enanthate has neither a direct effect on the testis nor on the epididymis: a study in adult male cynomolgus monkeys (Macaca fascicularis) Aris Junaidi, C Marc Luetjens, Joachim Wistuba, Axel Kamischke, Ching-Hei Yeung, Manuela Simoni and Eberhard Nieschlag Institute of Reproductive Medicine of the University, Domagkstr. 11, D-48149 Mu¨nster, Germany (Correspondence should be addressed to E Nieschlag; Email:[email protected]) A Junaidi is now at the Faculty of Veterinary Medicine, Gadjah Mada University, Jl. Olah Raga, Yogyakarta, Indonesia Abstract Objective: Norethisterone enanthate (NETE) is evaluated in trials of hormonal male contraception. It has been speculated that progestins may exert their contraceptive effects not only by suppressing gon- adotropins but also by direct effects on male organs. NETE was given to monkeys in which endogen- ous gonadotropin secretion was suppressed by a gonadotropin releasing hormone (GnRH) antagonist, and replaced by human follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG). If NETE has a direct effect on spermatogenesis and/or epididymal function, some changes in testicular histology, sperm motility and/or morphology should occur soon after exposure to NETE. Methods: Fifteen adult intact male monkeys were grouped and treated for a 38-day period. Group I received GnRH antagonist, FSH, hCG and NETE while group II received a regime identical to group I without NETE and group III received only NETE and vehicle. Ejaculates, body weight, testicular biop- sies and volume, and hormones were evaluated. Results: There was a similar pattern of serum FSH and testosterone in groups I and II.
    [Show full text]
  • Guidance on Bioequivalence Studies for Reproductive Health Medicines
    Medicines Guidance Document 23 October 2019 Guidance on Bioequivalence Studies for Reproductive Health Medicines CONTENTS 1. Introduction........................................................................................................................................................... 2 2. Which products require a bioequivalence study? ................................................................................................ 3 3. Design and conduct of bioequivalence studies .................................................................................................... 4 3.1 Basic principles in the demonstration of bioequivalence ............................................................................... 4 3.2 Good clinical practice ..................................................................................................................................... 4 3.3 Contract research organizations .................................................................................................................... 5 3.4 Study design .................................................................................................................................................. 5 3.5 Comparator product ....................................................................................................................................... 6 3.6 Generic product .............................................................................................................................................. 6 3.7 Study subjects
    [Show full text]
  • Study on Sperm Suppression Using Norethisterone Enanthate and Testosterone Undecanoate
    Study on sperm suppression using Norethisterone enanthate and testosterone undecanoate Objectives Overall goal: and The study was designed to address the following primary objectives: Background 1. The rate of suppression of spermatogenesis induced by a regimen of NET-EN and TU administered every 8 weeks for up to 4 injection visits; and 2. The level of contraceptive protection provided by the continued administration of NET-EN and TU every 8 weeks for an efficacy period of up to 56 weeks. Background: The study was designed to evaluate whether the combination of a progestin, norethisterone enantate (NET-EN), and an androgen, testosterone undecanoate (TU), represents a safe and effective method of male fertility regulation. The study had 3 phases. The suppression phase was to initiate a status of decreased sperm count and activity to a level which would be considered as contraceptive. When this was reached it was sustained with subsequent injections in the efficacy phase, which would end after 56 weeks, or if a pregnancy occurs. After these, the participant was then placed in the recovery phase, and was observed until normal sperm counts and activity returns to normal. 487 participants were screened for eligibility, of which 167 were excluded. The remaining 320 were enrolled into the study, into the suppression phase. A total of 274 completed the suppression phase. Of these 8 discontinued before transitioning to the Efficacy phase, and were moved to recovery phase. A total of 266 transitioned to the efficacy phase, among which 111 completed 56 weeks follow up or until a pregnancy occurred. The remaining 155 were discontinued, either because of the stopping of the study by the sponsor (96), death (1, unrelated to the study), or for other reasons (58).
    [Show full text]
  • Injectable Drug Delivery Systems for Steroids
    Injectable drug delivery systems for steroids Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) eingereicht im Fachbereich Biologie, Chemie, Pharmazie der Freien Universität Berlin vorgelegt von Stefanie Nippe aus Lübben März 2014 1. Gutachter: Professor Dr. R. Bodmeier 2. Gutachter: Privatdozent Dr. H. Kranz Disputation am 16.10.2014 II To my family III Danksagung Die vorliegende Arbeit wurde unter der Leitung von Herrn Professor Dr. Roland Bodmeier vom Institut für Pharmazie der Freien Universität Berlin sowie in der Abteilung Early Development der Bayer HealthCare AG angefertigt und vor Ort von Herrn Dr. Sascha General betreut. Mein besonderer Dank gilt meinem Doktorvater Herrn Prof. Dr. Roland Bodmeier für seine fachliche Betreuung und sein entgegengebrachtes Vertrauen, während der Zeit meiner wissenschaftlichen Arbeit. Herrn Priv-doz. Dr. Heiko Kranz danke ich ganz herzlich für die Bereitschaft die vorliegende Arbeit zu begutachten. Meinem Mentor Herrn Dr. Sascha General danke ich für die Bereitstellung meines Promotionsthemas, die Initiierung interdisziplinärer Zusammenarbeiten sowie die überlassene Freiheit zur Gestaltung der Arbeit. Bei Herrn Dr. Stefan Bracht möchte ich mich für die Möglichkeit zur Anfertigung dieser Dissertation sowie die finanzielle Unterstützung bedanken. Der Abteilung Analytical Development Physical Chemistry danke ich für die Möglichkeit zur Durchführung der umfangreichen Partikelgrößenuntersuchungen. Mein besonderer Dank gilt Herrn Sven Wegner für die hervorragende Einführung in die Messmethoden und seine Hilfsbereitschaft. Dr. Oliver-Martin Fischer und Dr. Andrea Rotgeri sowie der früheren Abteilung Nonclinical Pharmacokinetics, insbesondere Dr. Cornelia Preuße, danke ich herzlich für die Durchführung der in vivo Studien. Besonders bedanken möchte ich mich bei Andreas Eckermann für die gute Zusammenarbeit und Unterstützung.
    [Show full text]
  • Dosage Units of Steroids with a Seal Coating for the Steroids
    ~™ iiiiiii nun iiiiiiii inn mil mil inn iiiii inn urn mill mi mi m (19) J European Patent Office Office europeen des brevets (11) EP 0 927 556 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication:ation: (51) |nt. ci.6: A61 K 31/565, A61 K 9/28 07.07.1999 Bulletin 1999/27 (21) Application number: 97202908.6 (22) Date of filing: 23.09.1997 (84) Designated Contracting States: (72) Inventor: HARTHOLT GERTJAN PETER AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC 5406 BD UDEN (NL) NL PT SE (74) Representative: Kraak, Hajo (71) Applicant: Akzo Nobel N.V. N.V. Organon, 6824 BM Arnhem (NL) Postbus 20 5340 BH OSS (NL) (54) Dosage units of steroids with a seal coating for the steroids (57) Dosage units, such as tablet cores and gran- ules, containing a composition comprising a steroid having two hydrogen atoms at position 3 of the steroid skeleton, are coated. While a conventional sugar coat- ing process involves the application of several layers including, as a surface layer, a sugar coat, it was found that a seal coat such as normally used in a sugar coat- ing process can be used as the surface layer for the pur- pose of preventing the transfer of the steroid out of the composition. From this novel use of a seal coat, novel dosage units result. The process is advantageous, as it requires fewer steps than before. < CO LO LO r»- Csl o Q_ LU Printed by Xerox (UK) Business Services 2.16.7/3.6 1 EP 0 927 556 A1 Description ing the dosage unit to coating steps comprising the application of a seal coat.
    [Show full text]